PDF(Pubmed)
Abstract：
Hepatocellular carcinoma (HCC) is one of the most common and lethal malignant tumors in the world. Therapeutic options for advanced HCC are limited. Systemic treatment, especially with conventional cytotoxic drugs, is usually ineffective. For more than a decade, sorafenib has been the only systemic drug that has been proven to be clinically effective for treating advanced HCC. However, over the past three years, the rapid progress of molecular targeted therapies has dramatically changed the treatment landscape for advanced HCC. Immune checkpoint therapies are now being incorporated into HCC therapies, and their combination with molecular targeted therapy is emerging as a tool to enhance the immune response. In this review, we summarize the development and progress of molecular targeted agents and immunotherapies in HCC.
摘要：
肝细胞癌（HCC）是世界上最常见和最致命的恶性肿瘤之一。晚期HCC的治疗选择有限。系统性治疗,特别是传统的细胞毒性药物，通常是无效的。十多年来,索拉非尼是唯一被证明在临床上有效治疗晚期HCC的全身性药物。然而,在过去的三年里，分子靶向治疗的快速进展极大地改变了晚期HCC的治疗前景.免疫检查点疗法现在被纳入肝癌治疗，它们与分子靶向治疗的结合正在成为增强免疫反应的工具。在这次审查中,本文就肝癌分子靶向药物和免疫治疗的研究进展作一综述。
